Services
VitroScan offers services to support efficient and successful drug development by near clinical testing. Typical projects combine ex vivo 3D micro tumor testing using patient derived tumor tissue, benchmarking of responses based on proven predictive AI algorithms, and evaluation of target expression. Our services are tailored to the needs of customers and provide reliable data to successfully steer drug development processes and prevent failure of promising new treatments.
Near clinical testing capturing the real-world patient population
Reduce costs by effective selection of target indications
Identify optimal (combination) therapies by testing drugs in parallel
Enable rapid development by improved patient stratification
Proven predictive for true projections of clinical outcome
Reliable data for convincing market access strategy
Flexible project design supported by scientific experts
-
Select the indication and tissue of interest
-
Compare results against standard of care therapies
-
Annotate results with relevant clinical markers
-
Actionable reporting to guide succesful clinical development
Technology
Highly translational assays
A growing gap has emerged between research models in the lab and patients that require their new treatments. In a time of escalating costs, high attrition rates, limited resources and extended timelines, we need to invest in highly translational research.
Ex vivo 3D micro tumor testing pipeline
We offer accurate and reproducible testing of chemotherapy, small molecules, antibodies, ADCs and immotherapies and combination therapies in the native tumor microenvironment (TME).
The technology combines rapid ex vivo 3D tumor testing, capturing biologically relevant features of the drug & tissue interaction by image based analysis, followed quality controlled analysis and reporting of the patient's response to treatment.
Proven predictive and evaluated in clinical trials
The predictive value of the platform was etablished in a clinical trial for ovarian cancer patients. The Vitroscan Chemo Sensitivity Score adequately classifies patients RECIST response to standard of care platinum + taxane chemotherapy.
View data
Resources
Read the latest publications supporting VitroScan’s highly translational ex-vivo testing solutions and get in touch for more information on how we can help you de-risk your clinical development!
Posters
Scientific Publication
Koedoot et al., npj Precision Oncology, 2025
Publication of a study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.
VitroScan predictive testing solutions
Closer to the clinic
High quality standards
Qualified scientists in cancer cell biology & bioinformatics